Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition

Yaseen Hussain, Jing Hao Cui, Haroon Khan, Michael Aschner, Gaber El Saber Batiha, Philippe Jeandet

Research output: Contribution to journalReview articlepeer-review

Abstract

Epithelial to mesenchymal transition (EMT) is a physiological process that assumes a primary role in the induction of cancer metastasis. This results in increased cell renewal, and resistance to cell death and therapies. EMT, therefore, represents an effective strategy for regulating cancerous cell activity. A need for efficacy and low cytotoxicity epithelial to mesenchymal transition modifying drugs has led to the investigational testing of the efficacy of plethora of different groups of phytonutrients. Luteolin is a natural flavonoid inhibits the growth of cancer cells by various mechanisms, such as the stimulation of cancer cell apoptosis, cell cycle arrest, inhibition of cell replication, tumor growth, improvement of drug resistance, prevention of cancer cell intrusiveness and metastasis. This review article focuses on the anti-cancer and anti-metastatic potential of luteolin targeting various transcription factors, markers and signaling pathways associated with the repression of epithelial to mesenchymal transition.

Original languageEnglish (US)
Article number66
JournalMedical Oncology
Volume38
Issue number6
DOIs
StatePublished - Jun 2021

Keywords

  • Cancer metastasis
  • Epithelial to mesenchymal transition (EMT)
  • Luteolin
  • Luteolin and EMT

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition'. Together they form a unique fingerprint.

Cite this